

Press Release
August 17, 2022

Scandion Oncology extends PANTAX trial due to better-than-expected tolerability of SCO-101

Good tolerability allows for continued dose escalation in the dose-finding PANTAX phase 1b-trial with SCO-101 as combination therapy in pancreatic cancer. Consequently, readout from the trial is now expected in the first half of 2023.

Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, has observed a better-than-expected tolerability of its potential new cancer treatment SCO-101 in the dose-finding PANTAX phase 1b-trial. Thus, dosing is now escalated to higher levels than expected based on the initial findings in the CORIST trial, which prompted the amendment of the PANTAX trial design communicated in January 2021.

The continued dose escalation extends the PANTAX trial meaning it is now expected to read out in the first half of 2023 (previously expected in the third quarter of 2022). Trial execution is strong with good patient recruitment and the trial is progressing well.

PANTAX is a dose-finding phase 1b-trial in patients with unresectable or metastatic pancreatic cancer who are offered SCO-101 as an add-on therapy to their standard chemotherapy. The good tolerability of SCO-101 observed in this setting supports the overall profile of the compound as well tolerated in vulnerable patients.

“We have been positively surprised by the tolerability of SCO-101 observed in this trial, which further supports our belief in the potential of SCO-101 as a new cancer treatment improving options for patients. Naturally, we continue the dose escalation beyond our expectations in order to find the optimal dose of SCO-101 in this indication and combination, even if this of course postpones the readout from the trial”, says Bo Rode Hansen, President & CEO of Scandion.

Scandion is also currently carrying out the CORIST phase 2-trial in which SCO-101 is studied as combination therapy in patients with metastatic colorectal cancer. Topline data from the ongoing second part of this trial is still expected during the third quarter of 2022.

For further information please contact:

Mads Kronborg, Head of External Communication

Phone: +45 6051 4955

Email: ir@scandiononcology.com

This information is information that Scandion Oncology A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on August 17, 2022, at 08.30 CET.

Scandion Oncology (Scandion), the Cancer Drug Resistance Company, discovers and develops first-in-class medicines aimed at treating cancer which is resistant to current treatment options. We are at the forefront of this field, developing novel medicines that address cancer's resistance against treatment. Our aim is to make existing cancer treatments work better and longer, thereby potentially prolonging and improving the life of patients who would otherwise have a high risk of dying from their cancer.



Globally, close to 10 million patients die every year from cancer and approximately 90 percent of all cancer related deaths are due to cancer drug resistance. Our medicines could be relevant in several different cancers. That makes both our medical and commercial potential significant.

Scandion is based in Copenhagen and its lead candidate, SCO-101, is currently being studied in clinical phase I and II trials. The company is listed on Nasdaq First North Growth Market Sweden (ticker: SCOL).

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.